Journal of Korean Biological Nursing Science

Korean society of Biological Nursing Science (한국기초간호학회)
권호 표지
DOI QR코드

DOI QR Code

Comparison of Lipid Profile Ratios in Patients with High-grade Brain Cancers according to the Presence of Recurrence during Cancer-related Therapy

항암치료 받는 악성 뇌종양 환자의 재발여부에 따른 지질프로필 비율의 비교

  • Kim, Sanghee (College of Nursing.Research Institute of Nursing Science, Keimyung University)
  • 김상희 (계명대학교 간호대학.계명대학교 간호과학연구소)
  • Received : 2017.03.26
  • Accepted : 2017.05.17
  • Published : 2017.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The purpose of this study was to identify the lipid profile ratios as factors affecting disease progress in patients with high-grade primary brain cancers undergoing concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy. Methods: The levels of lipid profile ratios were evaluated by looking at the total cholesterol (TC) to high-density lipoprotein (HDL)-cholesterol (TC/HDL-c), low-density lipoprotein (LDL)-cholesterol to HDL-cholesterol (LDL-c/HDL-c), and triglycerides to HDL-cholesterol (TG/HDL-c). This descriptive research was conducted 7 months after the initiation of CCRT and adjuvant chemotherapy. Results: A total of 36 patients with newly diagnosed primary malignant brain cancer were included in the study. The levels of lipid profile ratios such as TC/HDL-c, LDL-c/HDL-c, TG/HDL-c were significantly different between the patients with and without disease progress at 7 months after initiation of CCRT and adjuvant chemotherapy. Conclusion: The lipid profile ratios were indicators affecting disease prognosis with tumor-related factors at 7 months after initiation of CCRT and adjuvant chemotherapy. Therefore, lipid profile ratios indicating hyperlipidemia in patients with high-grade brain cancers should be carefully monitored during and after cancer-related therapy.

Keywords

References

  1. The Korean Brain Tumor Society. Brain Cancers Epidemiology Page[Internet]. [cited 2015 March 13]. Available from: http://www.braintumor.or.kr/public/infor/sub2_1.php.
  2. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica. 2016; 131(6): 803-820. http://dx.doi.org/10.1007/s00401-016-1545-1
  3. National Cancer Information Center. The Types of Brain Cancers Page [Internet]. [cited 2016 May 2]. Available from:http://www.cancer.go.kr/mbs/cancer/jsp/cancer/cancer.jsp?cancerSeq=4301&menuSeq=4302&viewType=all&id=cancer_020118000000.
  4. Kim BS, Seol HJ, Nam DH, Park CK, Kim IH, Kim TM, Kim JH et al. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. Cancer Research and Treatment. 2017;49(1):193-203. http://dx.doi.org/10.4143/crt.2015.473
  5. Sarica FB, Cekinmez M, Tufan K, Sen O, Onal HC, Mertsoylu H et al. Five-year follow-up results for patients diagnosed with anaplastic astrocytoma and effectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma. Asian Journal of Neurosurgery. 2012; 7(4): 181-190. http://dx.doi.org/10.4103/1793-5482.106650
  6. Kumar N, Kumar P, Angurana SL, Khosla D, Mukherjee KK, Aggarwal R et al. Evaluation of outcome and prognostic factors in patients of glioblastoma multiforme: A single institution experience. Journal of Neurosciences in Rural Practice. 2013;4(5):46-55. http://dx.doi.org/10.4103/0976-3147.116455
  7. Marina O, Suh JH, Reddy CA, Barnett GH, Vogelbaum MA, Peereboom DM et al. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article. Journal of Neurosurgery. 2011;115(2):220-229. http://dx.doi.org/10.3171/2011.3.JNS10495
  8. Roy S, Lahiri D, Maji T, Biswas J. Recurrent Glioblastoma: Where we stand. South Asian Journal of Cancer. 2015;4(4):163-173. http://dx.doi.org/10.4103/2278-330X.175953
  9. Millan J, Pinto X, Munoz A, Zuniga M, Rubies-Prat J, Pallardo LF et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vascular Health and Risk Management. 2009; 5:757-765. https://doi.org/10.2147/VHRM.S6269
  10. Bielecka-Dabrowa A, Hannam S, Rysz J, Banach M. Malignancy-associated dyslipidemia. Open Cardiovascular Medicine Journal.2011;5:35-40. https://do i.org/10.2174/1874192401105010035
  11. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integrative Cancer Therapies.2004;3(4):294-300. https://doi.org/10.1177/1534735404270335
  12. Nelson RH. Hyperlipidemia as a Risk Factor for Cardiovascular Disease. Prim Care. 2013;40(1):195-211. https://doi.org/10.1016/j.pop.2012.11.003
  13. Upadhyay RK. Emerging Risk Biomarkers in Cardiovascular Diseases and Disorders. Journal of Lipids. 2015;8:971453. https://doi.org/10.1155/2015/971453
  14. Ghahremanfard F, Mirmohammadkhani M, Shahnazari B, Gholami G, Mehdizadeh J. The Valuable Role of Measuring Serum Lipid Profile in Cancer Progression. Oman Med J. 2015;3(5):353-357. https://doi.org/10.5001/omj.2015.71
  15. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK et al. Serum lipid profile and risk of prostate cancer recurrence: results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2349-2356. https://doi.org/10.1158/1055-9965.EPI-14-0458
  16. Gupta RK, Patel AK, Kumari R, Chugh S, Shrivastav C, Mehra S et al. Interactions between oxidative stress, lipid profile and antioxidants in breast cancer: a case control study. Asian Pacific Journal of Cancer Prevention. 2012;13(12): 6295-6298. https://doi.org/10.7314/APJCP.2012.13.12.6295
  17. McGrowder D, Riley C, Morrison EY, Gordon L. The Role of High-Density Lipoproteins in Reducing the Risk of Vascular Diseases, Neurogenerative Disorders, and Cancer. Cholesterol. 2011:1-9. https://doi.org/10.1155/2011/496925
  18. Mallick S, Benson R, Hakim A, Rath GK. Management of glioblastoma after recurrence: A changing paradigm. Journal of the Egyptian National Cancer Institute. 2016;28(4):199-210. http://dx.doi.org/10.1016/j.jnci.2016.07.001
  19. Yao X, Tian Z. Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies. Cancer Causes & Control. 2015;26(2):257-268. https://doi.org/10.1007/s10552-014-0507-y
  20. Givens DJ, Karnell LH, Gupta AK, Clamon GH, Pagedar NA, Chang KE et al. Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009; 135(12): 1209-1217. https://doi.org/10.1001/archoto.2009.174
  21. Li J, Wu MF, Lu HW, Zhang BZ, Wang LJ, Lin ZQ. Impact of Hyperglycemia on Outcomes among Patients Receiving Neoadjuvant Chemotherapy for Bulky Early Stage Cervical Cancer. PLoS One. 2016;11(11):1-15. http://dx.doi.org/10.1371/journal.pone.0166612
  22. Huang C, Freter C. Lipid Metabolism, Apoptosis and Cancer Therapy. International Journal of Molecular Sciences. 2015;16(1):924-949. https://doi.org/10.3390/ijms16010924.
  23. Wang Y, Wang ZQ, Wang FH, Lei XF, Yan SM, Wang DS et al. Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases. Oncotarget.2016;7(35):57290-57300. https://doi.org/10.18632/oncotarget.10145
  24. Dai D, Chen B, Wang B, Tang H, Li X, Zhao Z et al. Pretreatment TG/HDL-C Ratio Is Superior to Triacylglycerol Level as an Independent Prognostic Factor for the Survival of Triple Negative Breast Cancer Patients. Journal of Cancer.2016;7(12):1747-1754. https://doi.org/ 10.7150/jca.15776